The National Blood Authority (NBA) released the Guidelines on the Prophylactic Use of Rh D Immunoglobulin (Anti-D) in Obstetrics in 2003, with the aim of providing clinical guidance on antenatal prophylaxis. These guidelines also addressed supply constraints at the time of publication by including a staged implementation process for a full antenatal prophylaxis program in Australia.
The NBA met with the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) in October 2016 to discuss options to update Australia’s guidance on the use of Rh D immunoglobulin. The NBA and RANZCOG agreed that a new evidence-based guideline should be developed through a collaborative partnership between the NBA, RANZCOG and other relevant stakeholders.
The development of the guidance will be overseen by a multi-disciplinary Expert Reference Group (ERG) with expertise from a range of clinical settings to ensure they reflect current evidence and best clinical practice.
Expertise on the ERG includes:
- Obstetricians and Maternal fetal medicine experts
- General Practitioners
- Private pathology
- Australian Red Cross Blood Service
- Systematic review and guideline development support
The ERG will meet in October 2017 to discuss the scope of the systematic review.
The NBA and ERG will remain cognisant of the existing Rh D antenatal prophylaxis program throughout the guideline development process.